Amgen Inc. AMGN presented encouraging 52-week interim results from the open-label extension phase II study on AMG 334, which is being evaluated for the prevention of episodic migraine. Data were presented at the annual meeting of the American Headache Society (AHS).
The open-label study (n=383) was conducted to evaluate the safety and tolerability of AMG 334. Patients were given AMG 334 (70 mg) starting at week 12 for up to 256 weeks.
Results showed that when treated with AMG 334, patients witnessed a continued reduction in monthly migraine days at week 52, regardless of treatment received during the blinded phase. In addition, 62% of the patients on AMG 334 demonstrated a greater than 50% reduction in monthly migraine days with 38% getting a 75% or better response and nearly 1 in 5 experiencing 100% reduction in monthly migraine days at week 52.
Amgen also reported improvement in several other efficacy endpoints including a change in monthly migraine-specific medication use days and patient-reported outcomes using the Migraine Disability Assessment questionnaire. Moreover, the safety and tolerability profile of the candidate was found to be similar to that observed in the blinded phase of the study.
We remind investors that Amgen had reported positive results from the blinded phase II study on AMG 334 last month. Meanwhile, the company expects to advance AMG 334 into a phase III program later this year.
We note that Amgen was not the only company to present data at the AHS. Companies like Teva TEVA and Eli Lilly LLY also presented data on their migraine candidates, TEV-48125 and LY2951742, respectively. All are looking to bring their migraine treatments to the market.
Amgen currently carries a Zacks Rank #3 (Hold). Actelion Ltd. ALIOF is a better-ranked stock in the health care sector carrying a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment